U.S. Defense Reports Immuron's Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers' diarrhea

Stock Information for Immuron Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immuron Limited

Immuron to host Live Virtual Event
Immuron Travelan® sales continued strong growth
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Immuron Presentation Australian Biologics Festival 2024
Immuron achieves record Travelan® sales
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron achieves record half yearly Travelan® sales
Immuron Clinical Trials Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.